UCLA Scientists Develop Groundbreaking Immunotherapy for Pancreatic Cancer

Scientists at UCLA have developed a revolutionary “off-the-shelf” cell-based immunotherapy capable of tracking down and killing pancreatic cancer cells, even after they’ve metastasized to other organs.

In a recent mouse study, the treatment demonstrated remarkable results: it slowed cancer growth, extended survival rates, and maintained effectiveness within the challenging environment of solid tumors—offering new hope for a disease notorious for its poor prognosis and limited treatment options.

“Even when the cancer tries to evade one attack pathway by changing its molecular signature, our therapy is hitting it from multiple other angles at the same time. The tumor simply can’t adapt fast enough,” explained lead author Dr. Yanruide Li, a post-doctoral scholar at UCLA.

The innovative approach involves transforming human stem cells into invariant natural killer T cells (NKT cells), which are then genetically modified with a chimeric antigen receptor (CAR). This modification enables the cells to specifically recognize and attack pancreatic cancer cells using multiple mechanisms simultaneously.

What makes this therapy particularly promising is its universal compatibility with any immune system, eliminating the risk of dangerous rejection reactions. Unlike personalized immunotherapies that must be created individually for each patient, these engineered cells can be mass-produced from donated blood stem cells.

“One donor could provide sufficient cells for thousands of treatments,” researchers noted, highlighting the potential for a more affordable and accessible cancer treatment. The team estimates one dose could cost approximately $5,000—significantly less than current personalized CAR-T treatments that often run into hundreds of thousands of dollars.

Through rigorous testing in laboratory models, including scenarios where cancer was placed directly in the pancreas and others designed to mimic metastatic spread to organs like the liver and lungs, the research team observed remarkable capabilities in these engineered cells.

The CAR-NKT cells demonstrated an ability to penetrate deep into tumor tissue rather than remaining trapped on the periphery—a common limitation of many immunotherapies. Once inside, these cells could identify cancer cells through multiple recognition pathways and attack them using various built-in mechanisms.

Most impressively, the cells maintained their activity in the hostile tumor microenvironment. Typically, immune cells entering solid tumors quickly become exhausted and shut down, but these engineered cells continued functioning effectively.

“Developing a therapy that targets both the primary tumor and its metastases in pre-clinical studies—one that can be ready to use off-the-shelf—represents a fundamental shift in how we might treat this disease,” said senior author Dr. Lili Yang, a professor of microbiology, immunology and molecular genetics at UCLA.

This breakthrough could prove particularly significant for pancreatic cancer patients, who face some of the bleakest survival statistics among cancer sufferers. Pancreatic cancer is often diagnosed after it has already spread, and the tumor’s complex biology creates numerous physical and chemical barriers that diminish the effectiveness of conventional treatments.

The therapy’s versatility offers another advantage. Since it targets a protein common in several cancer types, the same cell product could potentially treat breast, ovarian, and lung cancers. In separate studies, the team has already demonstrated the therapy’s effectiveness against triple-negative breast cancer and ovarian cancer.

Based on these promising results, published in the Proceedings of the National Academy of Sciences (PNAS), UCLA researchers are preparing applications to the Food and Drug Administration to begin human clinical trials.

“We’ve developed a therapy that’s potent, safe, scalable and affordable,” Yang stated. “The next critical step is proving it can deliver the same results in patients we’ve seen in our preclinical work.”

Despite the optimism, researchers acknowledge important caveats. All testing thus far has been conducted in mice, and human tumors present greater complexity. Human cancers can evolve to lose the targets that treatments are designed to recognize, potentially allowing the cancer to escape detection and continue growing. Additionally, the long-term safety profile and potential side effects in humans remain unknown pending clinical trials.

Manufacturing challenges also exist, as producing large batches of identical, safe cells presents significant logistical and regulatory hurdles. Nevertheless, this innovative approach represents one of the most promising advances in pancreatic cancer treatment in recent years, potentially offering new hope for patients facing this devastating diagnosis.